Literature DB >> 8262674

Significance of epidermal growth factor receptor expression in primary human endometrial cancer.

G Scambia1, P Benedetti Panici, G Ferrandina, F Battaglia, M Distefano, G D'Andrea, R De Vincenzo, F Maneschi, F O Ranelletti, S Mancuso.   

Abstract

Radioreceptorial assessment of EGFR expression was prospectively performed on 60 primary human endometrial tumors. Of these, 26 were EGFR-positive while 13 expressed high EGFR levels. High EGFR levels correlated well with poor histopathological grading. No correlation with histopathological type, stage, myometrial invasion, lymph-node involvement or steroid hormone receptor status was observed. Disease-free survival rate was significantly shorter in the cases with high than in the cases with low EGFR levels. These results suggest a potential role of EGFR expression assessment in prognostic characterization of endometrial cancer patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8262674     DOI: 10.1002/ijc.2910560106

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  18 in total

Review 1.  Modern trends into the epidemiology and screening of ovarian cancer. Genetic substrate of the sporadic form.

Authors:  Maria Koutsaki; Apostolos Zaravinos; Demetrios A Spandidos
Journal:  Pathol Oncol Res       Date:  2011-12-09       Impact factor: 3.201

2.  A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study.

Authors:  Kimberly K Leslie; Michael W Sill; Edgar Fischer; Kathleen M Darcy; Robert S Mannel; Krishnansu S Tewari; Parviz Hanjani; Jason A Wilken; Andre T Baron; Andrew K Godwin; Russell J Schilder; Meenakshi Singh; Nita J Maihle
Journal:  Gynecol Oncol       Date:  2013-02-21       Impact factor: 5.482

3.  Sulfated glycolipid PG545 induces endoplasmic reticulum stress and augments autophagic flux by enhancing anticancer chemotherapy efficacy in endometrial cancer.

Authors:  Robert Hoffmann; Sayantani Sarkar Bhattacharya; Debarshi Roy; Boris Winterhoff; Ralf Schmidmaier; Keith Dredge; Edward Hammond; Viji Shridhar
Journal:  Biochem Pharmacol       Date:  2020-04-28       Impact factor: 5.858

4.  Promoter hypomethylation of EpCAM-regulated bone morphogenetic protein gene family in recurrent endometrial cancer.

Authors:  Ya-Ting Hsu; Fei Gu; Yi-Wen Huang; Joseph Liu; Jianhua Ruan; Rui-Lan Huang; Chiou-Miin Wang; Chun-Liang Chen; Rohit R Jadhav; Hung-Cheng Lai; David G Mutch; Paul J Goodfellow; Ian M Thompson; Nameer B Kirma; Tim Hui-Ming Huang
Journal:  Clin Cancer Res       Date:  2013-09-27       Impact factor: 12.531

Review 5.  Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab.

Authors:  Toni M Brand; Mari Iida; Deric L Wheeler
Journal:  Cancer Biol Ther       Date:  2011-05-01       Impact factor: 4.742

Review 6.  Emerging therapeutic targets in endometrial cancer.

Authors:  Konstantin J Dedes; Daniel Wetterskog; Alan Ashworth; Stan B Kaye; Jorge S Reis-Filho
Journal:  Nat Rev Clin Oncol       Date:  2011-01-11       Impact factor: 66.675

7.  A novel angiogenic role for prostaglandin F2alpha-FP receptor interaction in human endometrial adenocarcinomas.

Authors:  Kurt J Sales; Tammy List; Sheila C Boddy; Alistair R W Williams; Richard A Anderson; Zvi Naor; Henry N Jabbour
Journal:  Cancer Res       Date:  2005-09-01       Impact factor: 12.701

8.  Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma.

Authors:  M Maurizi; G Almadori; G Ferrandina; M Distefano; M E Romanini; G Cadoni; P Benedetti-Panici; G Paludetti; G Scambia; S Mancuso
Journal:  Br J Cancer       Date:  1996-10       Impact factor: 7.640

9.  HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer.

Authors:  G E Konecny; L Santos; B Winterhoff; M Hatmal; G L Keeney; A Mariani; M Jones; C Neuper; B Thomas; L Muderspach; D Riehle; H-J Wang; S Dowdy; K C Podratz; M F Press
Journal:  Br J Cancer       Date:  2008-12-16       Impact factor: 7.640

10.  Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy.

Authors:  G Scambia; P Benedetti-Panici; G Ferrandina; M Distefano; G Salerno; M E Romanini; A Fagotti; S Mancuso
Journal:  Br J Cancer       Date:  1995-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.